]>
IRCT2017012832249N1 IRCT 2017-04-10 Vice chancellor for research, Tehran University of Medical Sciences The effect of positive airway pressure (PAP) therapy on the components of metabolic syndrome in obstructive sleep apnea (OSA) Positive airway pressure (PAP) therapy and its impact on the components of metabolic syndrome in obstructive sleep apnea (OSA) patients 2017-04-21 anticipated 40 Complete https://irct.ir/trial/25168 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. N/A Obstructive Sleep Apnea. PAP therapy.
public Mohammad Mehraban
Baharloo Hospital, Behdari St., Rahahan Sq.
Tehran Iran (Islamic Republic of) +98 21 5567 7333 dr_m_mehraban@yahoo.com Tehran University of Medical Sciences scientific Zahra Banafsheh Alemohammad
Baharloo Hospital, Behdari St., Rahahan Sq.
Tehran Iran (Islamic Republic of) +98 21 5567 7333 alemohammadz@sina.tums.ac.ir Tehran University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria consist of adult patients with OSA and clinical indication for PAP therapy. Exclusion criteria consist of pregnancy, cardiopulmonary disorder, upper airway cancer or surgery, change or new administration of drug for hyperlipidemia, hypertension and diabetes mellitus. 14 years 85 years Both G47.3 A disorder characterized by cessation of breathing for short periods during sleep Treatment - Devices PAP therapy Blood pressure. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: Sphygomanometer. High density lipoprotein. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: Direct Enzymatic Colorimetric Method. Fasting blood sugar. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: glucose oxidase assay. Triglyceride. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: lipase peroxidase colorometric. Abdominal Circumference. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: Metre. Weight. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: scale. Body Mass Index. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: scale and stadiometer. C reactive protein. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: quantitative latex immunoturbidimetric assay. Erythrocyte sedimentation rate. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: the Westergren method (therma). Alkaline phosphatase. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: nitrophenyl phosphate kinetic. Complete blood count. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: cell counter. Hemoglobin A1c. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: High Performance Liquid Chromatography. Alanine amino transferase. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: NADH Kinetic UV. Aspartate amino tranferase. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: NADH Kinetic UV. Uric acid. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: enzymatic colorimetric. Cholesterol. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: cholestrol oxidase peroxidase colorimetric. 25 hydroxy vitamin D3. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: High Performance Liquid Chromatography. Creatinine. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: jaffe kinetic colorimetric. Blood urea nitrogen. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: Urease GLDH Kinetic. Low density lipoprotein. Timepoint: before treatment and 3 months following beginning of the treatment. Method of measurement: Direct Enzymatic colorimetric. Vice chancellor for research, Tehran University of Medical Sciences Approved 2017-01-28 Ethics committee of Tehran University of Medical Sciences Tehran University of Medical Sciences, Ghods Ave., Keshavarz Blvd. Tehran Iran (Islamic Republic of)